Clearmind completes Part C enrolment in CMND-100 alcohol use disorder trial
The company says recruitment is finished for the randomised, placebo-controlled multiple-dose part of its Phase I/IIa study of a non-hallucinogenic psychedelic-derived candidate.
Clearmind Medicine announced on 16 November 2026 that it has completed patient enrolment in Part C of its Phase I/IIa clinical trial of CMND-100, a candidate for alcohol use disorder (AUD). The company describes the compound as non-hallucinogenic and derived from psychedelic chemistry.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Clearmind Medicine Inc. ↗
Article written by VigiEye from the official source (Clearmind Medicine Inc.). Claims are the company's own. AI-assisted; check the source before acting.